Applied Therapeutics (APLT) Competitors $0.44 -0.01 (-2.03%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.68%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. DRUG, GALT, ACB, LRMR, ALLO, ALMS, AVTE, DSGN, FENC, and TVRDShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Allogene Therapeutics (ALLO), Alumis (ALMS), Aerovate Therapeutics (AVTE), Design Therapeutics (DSGN), Adherex Technologies (FENC), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Its Competitors Bright Minds Biosciences Galectin Therapeutics Aurora Cannabis Larimar Therapeutics Allogene Therapeutics Alumis Aerovate Therapeutics Design Therapeutics Adherex Technologies Tvardi Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends. Which has better earnings and valuation, DRUG or APLT? Bright Minds Biosciences has higher earnings, but lower revenue than Applied Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-109.69Applied Therapeutics$460K135.42-$105.62M-$0.43-1.02 Does the media favor DRUG or APLT? In the previous week, Bright Minds Biosciences had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 2 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.93 beat Bright Minds Biosciences' score of 0.92 indicating that Applied Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, DRUG or APLT? Bright Minds Biosciences has a beta of -6.07, meaning that its stock price is 707% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Is DRUG or APLT more profitable? Bright Minds Biosciences' return on equity of -14.56% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% Applied Therapeutics N/A -184.67%-84.02% Do institutionals & insiders hold more shares of DRUG or APLT? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate DRUG or APLT? Bright Minds Biosciences presently has a consensus price target of $83.25, suggesting a potential upside of 110.81%. Applied Therapeutics has a consensus price target of $6.10, suggesting a potential upside of 1,286.36%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryBright Minds Biosciences beats Applied Therapeutics on 9 of the 15 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.30M$3.04B$5.51B$9.83BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-1.0217.6930.0325.33Price / Sales135.42360.59447.53104.15Price / CashN/A40.7324.8128.01Price / Book0.909.138.715.87Net Income-$105.62M-$54.75M$3.26B$265.22M7 Day Performance-7.47%-0.16%0.90%1.13%1 Month Performance6.31%8.12%3.65%2.45%1 Year Performance-92.45%24.55%46.29%27.99% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.4276 of 5 stars$0.44-2.0%$6.10+1,286.4%-92.8%$62.30M$460K-1.0230News CoverageUpcoming EarningsGap DownDRUGBright Minds Biosciences2.4209 of 5 stars$35.13-1.3%$83.25+137.0%+3,375.3%$251.43MN/A-99.21N/ANews CoverageUpcoming EarningsGALTGalectin Therapeutics2.4993 of 5 stars$3.74-0.8%$6.00+60.5%+90.2%$237.97MN/A-5.229ACBAurora Cannabis0.5262 of 5 stars$4.17-1.8%N/A-19.3%$235.39M$343.29M38.051,130Trending NewsEarnings ReportAnalyst RevisionLRMRLarimar Therapeutics2.9178 of 5 stars$3.65-3.3%$18.50+407.4%-50.8%$235.37MN/A-2.4730Positive NewsUpcoming EarningsALLOAllogene Therapeutics3.1901 of 5 stars$1.10+3.3%$8.44+671.2%-55.6%$232.95MN/A-0.87310News CoverageUpcoming EarningsALMSAlumis2.8508 of 5 stars$4.27-2.3%$19.80+363.7%-63.7%$232.60MN/A0.00N/AAVTEAerovate TherapeuticsN/A$7.94+8.9%N/A-87.3%$230.14MN/A-2.6620News CoverageHigh Trading VolumeDSGNDesign Therapeutics0.1429 of 5 stars$4.03-7.4%N/A+13.7%$228.84MN/A-4.0740News CoverageEarnings ReportFENCAdherex Technologies2.3207 of 5 stars$8.22+0.7%$13.00+58.2%+39.1%$228.63M$30.91M-16.1210News CoverageUpcoming EarningsAnalyst DowngradeTVRDTvardi TherapeuticsN/A$23.73-1.7%$64.25+170.8%N/A$222.14MN/A0.0080 Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives Galectin Therapeutics Alternatives Aurora Cannabis Alternatives Larimar Therapeutics Alternatives Allogene Therapeutics Alternatives Alumis Alternatives Aerovate Therapeutics Alternatives Design Therapeutics Alternatives Adherex Technologies Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access